NCT07472972Recruiting
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
Summary
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy. This assay combines five components for longitudinal profiling of each patient. The goal of the trial is that the assay can be completed (feasibility). This comprehensive assay integrates five key components including circulating tumor DNA (CAPPseq), inflammation markers from peripheral blood tests (InflaMIX), PET CT imaging parameters, immune cell profiles (flow cytometry), and performance status (ECOG). Ultimately, this tool could improve treatment selection, and guide more personalized therapy decisions for lymphoma patients receiving CAR T cells.
Inclusion criteria
• Written informed consent before registration and prior to any trial specific procedures • Participants ≥ 18 years of age • Diagnosis of relapse/refractory B-cell lymphoma according to WHO 2022 classification • Measurable disease per response criteria specific to the disease e.g. per Lugano 2014 criteria • Patients planned for CD19-redirected CAR T cell therapy according to clinical standard of care • Patients who are willing to donate peripheral blood and biopsy material at indicated clinical visits
Exclusion criteria
• Any condition, which precludes initiation of CD19-redirected CAR T cell therapy (e.g. breast feeding, pregnancy, infections, etc.) as judged by the treating physician • Any coexisting medical or psychological condition that would preclude participation in the required study procedures, as judged by the treating physician • Unwillingness or inability to comply with the protocol
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland
- Sponsor
- University of Zurich(Other)
- Protocol no.
- INTeRCePT2.0
- Conditions
- Lymphoma, Lymphoid Hematological Malignancies
- Interventions
- —
Collaborators
University Hospital, Zürich, ETH Zurich
Locations · 1
- Zurich, SwitzerlandUniversityhospital Zurich, Department of Medical Oncology and HematologyRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: March 16, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
Other identifiers
- BASEC-Nr. 2024-02540 · other identifier
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.